{
    "id": 6817,
    "fullName": "MAPK1 E322K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MAPK1 E322K lies within the protein kinase domain of the Mapk1 protein (UniProt.org). E322K confers a gain of function to the Mapk1 protein as demonstrated by constitutive Mapk1 phosphorylation (PMID: 16273204), and has been demonstrated to confer resistance to Raf/Mek inhibitors in culture (PMID: 27760319).",
            "references": [
                {
                    "id": 2867,
                    "pubMedId": 16273204,
                    "title": "A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16273204"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5594,
        "geneSymbol": "MAPK1",
        "terms": [
            "MAPK1",
            "ERK",
            "ERK-2",
            "ERK2",
            "ERT1",
            "MAPK2",
            "p38",
            "p40",
            "p41",
            "p41mapk",
            "p42-MAPK",
            "P42MAPK",
            "PRKM1",
            "PRKM2"
        ]
    },
    "variant": "E322K",
    "createDate": "05/31/2015",
    "updateDate": "07/17/2018",
    "referenceTranscriptCoordinates": {
        "id": 145593,
        "transcript": "NM_002745",
        "gDna": "chr22:g.21772875C>T",
        "cDna": "c.964G>A",
        "protein": "p.E322K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3814,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Tarceva (erlotinib) treatment resulted in disease-free survival for more than 2 years in an oral cavity squamous cell carcinoma patient harboring MAPK1 E322K mutation (PMID: 26181029).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4188,
                    "pubMedId": 26181029,
                    "title": "Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26181029"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2331,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 E322K demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2332,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 E322K demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2330,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 E322K demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 E322K and Y233A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30179,
                "profileName": "BRAF V600E MAPK1 Y233A MAPK1 E322K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14915,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 E322K in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30380,
                "profileName": "BRAF V600E MAPK1 E322K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E322K were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30380,
                "profileName": "BRAF V600E MAPK1 E322K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E322K were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30380,
                "profileName": "BRAF V600E MAPK1 E322K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6671,
            "profileName": "MAPK1 E322K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30179,
            "profileName": "BRAF V600E MAPK1 Y233A MAPK1 E322K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30380,
            "profileName": "BRAF V600E MAPK1 E322K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145593,
            "transcript": "NM_002745",
            "gDna": "chr22:g.21772875C>T",
            "cDna": "c.964G>A",
            "protein": "p.E322K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145594,
            "transcript": "NM_138957",
            "gDna": "chr22:g.21772875C>T",
            "cDna": "c.964G>A",
            "protein": "p.E322K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}